According to DelveInsight's analysis, the demand for occlusion devices is largely driven by the growing number of patients affected by various chronic conditions. Additionally, rapid technological advancements, rising preference for minimally invasive surgeries (MIS), favorable reimbursement policies for MIS, and an expanding geriatric population are key factors contributing to the overall growth of the occlusion devices market between 2024 and 2030. DelveInsight's \"Occlusion Devices Market Insights, Competitive Landscape and Market Forecast-2030\" report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Occlusion Devices companies actively working in the market.\n\nOcclusion devices are medical tools used to block or close blood vessels or other body passages to treat various conditions. They are commonly used in procedures such as closing abnormal blood flow pathways, sealing heart defects, or blocking blood supply to tumors. These devices can be made from materials like metal, polymer, or fabric and are often delivered through minimally invasive catheter-based techniques.\n\nThe global occlusion devices market is projected to expand at a compound annual growth rate (CAGR) of 6.31% between 2024 and 2030. Geographically, in 2023, North America is projected to hold the largest share of the occlusion devices market. This growth is driven by factors such as the increasing prevalence of cardiovascular diseases, rising cancer cases, and neurological conditions like brain aneurysms, alongside rapid advancements in device technology and new government initiatives promoting disease treatment awareness.\n\nRecent developments in the market include: in February 2022, Front Line Medical Technologies announced the launch and distribution of COBRA-OS (Control of Bleeding, Resuscitation, Arterial Occlusion System), a device capable of withstanding aortic pressure while enabling permissive hypotension in areas below the balloon, reducing the risk of hemorrhage. It is the smallest life-saving device for bleeding control. In July 2021, Terumo Medical Corporation (TMC) announced the launch of its AZUR Vascular Plug, the only device compatible with a microcatheter that can occlude arteries up to 8 mm in diameter. In September 2020, Boston Scientific Corporation received FDA approval to launch the WATCHMAN FLX, a Left Atrial Appendage Closure (LAAC) device designed to seal the heart's left atrial appendage and prevent the formation of blood clots.\n\nThe COVID-19 pandemic had a considerable impact on the occlusion devices market, primarily due to the restructuring of healthcare systems in response to strict global lockdowns. Treating COVID-19 patients became the top priority, while individuals with chronic conditions, especially those with heart valve diseases, were classified as non-urgent, resulting in delays in their treatment procedures. Factors such as blood vessel damage or trauma, smoking, hypertension, and genetic predisposition contribute to the risk of developing brain aneurysms. Treatment options include medical therapy, surgical clipping, endovascular therapy, or coiling, with or without adjunctive devices. According to WHO statistics from August 2021, approximately 1.28 billion adults aged 30-79 worldwide had hypertension, with about two-thirds living in low- and middle-income countries. The rising prevalence of hypertension is expected to increase cardiovascular disease cases, thereby driving demand for occlusion devices used in cardiovascular treatments. Consequently, due to these factors, the demand for neurology occlusion devices is anticipated to rise, contributing to overall growth in the occlusion devices market during the forecast period.\n\nThe report covers the following segments: By Product Type - Sealants & Adhesives, Staplers, Sutures [Absorbable and Non-Absorbable], Hemostats, and Others; By End User - Hospitals, Clinics, and Others; By Geography - North America, Europe, Asia-Pacific, and Rest of the World; and includes key market players such as Abbott, Acrostak Int., Terumo Corporation, Edwards Lifesciences Corporation, Cordis, B. Braun SE, Cook, Medtronic, Cardinal Health, AngioDynamics, Integer Holdings Corporation, Acandis GmbH, Penumbra, Inc., LeMaitre Vascular Inc., Lepu Medical, Stryker, Boston Scientific Corporation, Artio Medical Inc., KYOTO MEDICAL PLANNING Co., Ltd., Kaneka Medix Corporation, and others. The report also includes Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, and Analyst's View.

Global Occlusion Devices Market to grow at a CAGR of 6.31% by 2030, Evaluates DelveInsight

DelveInsight's market report analyzes the global occlusion devices market, projecting a compound annual growth rate (CAGR) of 6.31% from 2024 to 2030. The growth is driven by rising prevalence of chronic conditions, increasing demand for minimally invasive surgeries, favorable reimbursement policies, and an expanding geriatric population. Key factors include cardiovascular diseases, cancer, and neurological conditions like brain aneurysms. North America is projected to hold the largest market share in 2023. The report highlights recent product launches such as Front Line Medical Technologies' COBRA-OS, Terumo Medical Corporation's AZUR Vascular Plug, and Boston Scientific's WATCHMAN FLX, as well as the impact of the COVID-19 pandemic on treatment delays. It covers market segments by product type, end user, and geography, and includes key players such as Abbott, Terumo, Edwards Lifesciences, Boston Scientific, and others.